BACKGROUND: Approximately 10% of patients hospitalized with community‐acquired
pneumonia (CAP) are bacteremic. Bacteremic Streptococcus pneumoniae pneumonia …

The purpose of this study was to examine the impact of antimicrobial monotherapy vs
combination therapy on length of stay and mortality for patients with Streptococcus …

Retrospective studies have suggested that combination antibiotic therapy for severe
bacteremic pneumococcal pneumonia may reduce mortality. We assessed this issue in a …

Streptococcus pneumoniae is the leading cause of community-acquired pneumonia (CAP)
and accounts for approximately two-thirds of cases of CAP associated with mortality [1]. The …

Background The majority of community-acquired pneumonia (CAP) patients (about 80%)
will be treated as outpatients, because therapy with a single agent will work. For the …

Background Although monotherapy for pneumococcal pneumonia is standard, a survival
benefit of combination β-lactam and macrolide therapy has been suggested. Hypothesis …

To assess the association between inclusion of a macrolide in a β-lactam—based empirical
antibiotic regimen and mortality among patients with bacteremic pneumococcal pneumonia …

Objective Combining a macrolide or a fluoroquinolone to beta-lactam regimens in the
treatment of patients with moderate to severe community-acquired pneumonia is …

Sir—In a previously published article [1], we showed that adults 50 years of age with
invasive Streptococcus pneumoniae pneumonia given combination antibiotic therapy …

Community-acquired pneumonia (CAP) is a common and potentially serious illness that is
associated with morbidity and mortality. Although medical care has improved during the past …